Droxidopa Oral Product

Preclinical

SStephen G. Kaler

Droxidopa Oral Product is one of 8 therapeutic programs targeting Menkes disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Menkes DiseaseRecruiting

Menkes DiseasePreclinical

Recruiting

Competition

Competitive Landscape

9 competitors in Menkes Disease

#DrugCompanyPhaseTrials

Fludara

Jakafi

Dacogen

Sun Pharmaceutical Industries, Inc.

Approved

—4

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Busulfex

Alkeran

Northera

2 8

Droxidopa Oral Product

SStephen G. Kaler

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

PreclinicalRecruiting

Menkes Disease

NCT07398508

Clinical

Trials by Indication[1]

Menkes disease1 trial

Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease: Double-blind Placebo-controlled Randomized Crossover Clinical Trial

Recruiting·SStephen G. Kaler·Preclinical·NCT07398508·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Droxidopa Oral Product. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Droxidopa Oral Product. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Stephen G. Kaler company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SStephen G. Kaler

Droxidopa Oral Product

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Menkes disease1 trial

References

Drug Info

Quick Facts

Related News